Metagenomi, Inc. (NASDAQ:MGX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Metagenomi, Inc. (NASDAQ:MGX) have been given a consensus recommendation of “Moderate Buy” by the seven research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $16.67.

Several analysts have recently commented on MGX shares. HC Wainwright increased their price objective on shares of Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. Chardan Capital reaffirmed a “buy” rating and set a $15.00 price target on shares of Metagenomi in a research report on Wednesday, November 20th.

Institutional Trading of Metagenomi

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MGX. Rhumbline Advisers purchased a new stake in shares of Metagenomi in the second quarter valued at approximately $26,000. XTX Topco Ltd purchased a new stake in Metagenomi in the 2nd quarter worth $66,000. Novo Holdings A S raised its position in Metagenomi by 3.5% during the second quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock worth $7,344,000 after acquiring an additional 60,825 shares during the period. Green Alpha Advisors LLC purchased a new position in Metagenomi during the third quarter valued at $69,000. Finally, BNP Paribas Financial Markets grew its position in shares of Metagenomi by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after purchasing an additional 7,256 shares during the period.

Metagenomi Trading Down 2.0 %

Shares of NASDAQ MGX opened at $2.97 on Friday. Metagenomi has a 52 week low of $1.61 and a 52 week high of $12.74. The business’s 50 day moving average price is $2.90 and its 200 day moving average price is $2.92.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.